September 29, 2021 11:00am EST ABSTRACT Understanding the tissue-specific genetic architecture of protein levels is instrumental to understand the biology of health and disease. We
September 1, 2021 8:00am PT/11:00 am ET ABSTRACT COPD and emphysema are lung diseases related to chronic exposure to tobacco smoke or air pollution. The
Register Now | July 27th 2021 11am EST ABSTRACT The NIH-funded Atherosclerosis Risk in Communities (ARIC) Study, which began in 1987, is a treasure trove
Our presentation at the virtual 2021 Global Nash Congress features Dr. Stephen Williams , who discusses SomaLogics development of serum proteomic tests for liver biopsy components and diagnosis of at-risk NASH. Watch now to learn how these tests can help streamline clinical trials.
As part of the Molecular Medicine Tri-Con virtual conference on February 16, 2021, Dr. Sheri Wilcox of SomaLogic described how the SomaScan Assay has been used to identify protein patterns as surrogates for clinical outcomes, discover proteins associated with disease states, and correlate protein measurements with genetic variants.
On January 27, 2021, Dr. Svati Shah (Duke University School of Medicine), Dr. Stephen Williams (SomaLogic) and Dr. Naveed Sattar (University of Glasgow) discussed how proteomic models can be implemented to design more precise treatment strategies for diabetic patients.
As part of the Translational Dx Virtual Summit on September 23, 2020, Dr. Sheri Wilcox, Senior Director, Scientific Liaison and Technical Services, at SomaLogic described the utility of the SomaScan Assay in oncology applications.
Protein-genotype associations (pQTLs) are an important tool for identifying proteins that link genetic variants with disease states. On August 6, 2020, Dr. Benjamin Sun discussed how he and his colleagues at the University of Cambridge used the SomaScan® Assay to develop a pQTL atlas for the human plasma proteome.
On June 25, 2020, Dr. Kevin Coombs of the University of Manitoba described his work using the SomaScan Assay to identify biological processes associated with infection by Zika virus and various strains of influenza. He also discussed how the SomaScan Assay® could be used to further study infectious disease, including the current COVID-19 pandemic, in the immediate future.
It was recently demonstrated that the SomaScan Assay, a multiplex proteomics platform, can noninvasively and simultaneously predict all the key elements of the liver biopsy: liver fat, inflammation, hepatocyte ballooning and fibrosis based only on serum protein biomarkers.
On May 12, 2020, Dr. Stephen Williams (SomaLogic), Dr. Claudia Langenberg (University of Cambridge), and Dr. Peter Ganz (UCSF) discussed their recent proof-of-concept study that illustrated how measuring blood proteins at scale could lead to a future comprehensive “liquid health check.” They also explored the implications of their findings for public health, particularly in the areas of diabetes and cardiovascular disease.
In this Webinar, Karsten Suhre, Director of the Bioinformatics Core at Weill Cornell Medicine-Qatar, will discuss how proteomics can complement GWAS and EWAS
In this webinar, Lehallier and Barzilai discuss the findings of their Nature Medicine paper “Undulating changes in human plasma proteome profiles across the lifespan.”
